Sustained Release Strategy Designed for Lixisenatide Delivery to Synchronously Treat Diabetes and Associated Complications.

Zhuang Y, Yang X, Li Y, Chen Y, Peng X, Yu L, Ding J

ACS applied materials & interfaces9 Aug 2019Cited by 45 (Europe PMC)

PMID31361112DOI10.1021/acsami.9b10346PepBankPUB-31361112

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone11

In this study, Lixisenatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Lixisenatide.

01AnimalNot a test of Lixisenatide aloneAnimal study (in vivo)Pharmacokinetics
In vivo release studies showed sustained lixisenatide release from the mixture hydrogel for up to 9 days.
In plain wordsIn animals, the mixture hydrogel sustained lixisenatide release for up to 9 days.
Peptide
Lixisenatide
Outcome
Not applicableSustained release in vivo
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
Both in vitro and in vivo release studies demonstrated that the mixture hydrogel provided the sustained release of Lixi for up to 9 days, which was attributed to balanced electrostatic interactions between the positive charges in the peptide and the negative charges in the polymer carrier.
1 context sentence(design, population, supporting numbers)
Summary · context
Herein, we aimed to develop a long-acting delivery system of lixisenatide (Lixi), a glucose-dependent antidiabetic peptide, based on an injectable hydrogel for the synchronous treatment of type 2 diabetes mellitus (T2DM) and associated complications.
In this study, Lixisenatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Lixisenatide.
Report a problemFND-3136111202
02AnimalNot a test of Lixisenatide aloneAnimal study (in vivo)Efficacy outcome
In diabetic db/db mice, one hydrogel lixisenatide injection provided comparable glucose lowering to twice-daily lixisenatide solution for up to 9 days.
In plain wordsIn mice, one hydrogel lixisenatide injection lowered glucose comparably to twice-daily lixisenatide solution for up to 9 days.
Peptide
Lixisenatide
Outcome
Direction not reportedHypoglycemic efficacy
Study
mousen: not reported in source
Diabetic db/db mice
Comparator
Twice-daily lixisenatide solution
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The hypoglycemic efficacy of Lixi delivered from the mixture hydrogel after a single subcutaneous injection into diabetic db/db mice was comparable to that of twice-daily administrations of Lixi solution for up to 9 days.
1 context sentence(design, population, supporting numbers)
Summary · context
Herein, we aimed to develop a long-acting delivery system of lixisenatide (Lixi), a glucose-dependent antidiabetic peptide, based on an injectable hydrogel for the synchronous treatment of type 2 diabetes mellitus (T2DM) and associated complications.
In this study, Lixisenatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Lixisenatide.
Report a problemFND-3136111203
03AnimalNot a test of Lixisenatide aloneAnimal study (in vivo)Efficacy outcome
In diabetic mice, three hydrogel lixisenatide administrations within a month significantly increased plasma insulin.
In plain wordsIn mice, three hydrogel lixisenatide administrations within a month increased plasma insulin.
Peptide
Lixisenatide
Outcome
IncreasePlasma insulin
Study
mousen: not reported in source
Diabetic db/db mice
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Furthermore, three successive administrations of the abovementioned gel system within a month significantly increased the plasma insulin level, lowered glycosylated hemoglobin, and improved the pancreatic function of the animals.
1 context sentence(design, population, supporting numbers)
Summary · context
Herein, we aimed to develop a long-acting delivery system of lixisenatide (Lixi), a glucose-dependent antidiabetic peptide, based on an injectable hydrogel for the synchronous treatment of type 2 diabetes mellitus (T2DM) and associated complications.
In this study, Lixisenatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Lixisenatide.
Report a problemFND-3136111204
04AnimalNot a test of Lixisenatide aloneAnimal study (in vivo)Efficacy outcome
In diabetic mice, three hydrogel lixisenatide administrations within a month lowered glycosylated hemoglobin.
In plain wordsIn mice, three hydrogel lixisenatide administrations within a month lowered glycosylated hemoglobin.
Peptide
Lixisenatide
Outcome
DecreaseGlycosylated hemoglobin
Study
mousen: not reported in source
Diabetic db/db mice
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Furthermore, three successive administrations of the abovementioned gel system within a month significantly increased the plasma insulin level, lowered glycosylated hemoglobin, and improved the pancreatic function of the animals.
1 context sentence(design, population, supporting numbers)
Summary · context
Herein, we aimed to develop a long-acting delivery system of lixisenatide (Lixi), a glucose-dependent antidiabetic peptide, based on an injectable hydrogel for the synchronous treatment of type 2 diabetes mellitus (T2DM) and associated complications.
In this study, Lixisenatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Lixisenatide.
Report a problemFND-3136111205
05AnimalNot a test of Lixisenatide aloneAnimal study (in vivo)Efficacy outcome
In diabetic mice, three hydrogel lixisenatide administrations within a month improved pancreatic function.
In plain wordsIn mice, three hydrogel lixisenatide administrations within a month improved pancreatic function.
Peptide
Lixisenatide
Outcome
Direction not reportedPancreatic function
Study
mousen: not reported in source
Diabetic db/db mice
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Furthermore, three successive administrations of the abovementioned gel system within a month significantly increased the plasma insulin level, lowered glycosylated hemoglobin, and improved the pancreatic function of the animals.
1 context sentence(design, population, supporting numbers)
Summary · context
Herein, we aimed to develop a long-acting delivery system of lixisenatide (Lixi), a glucose-dependent antidiabetic peptide, based on an injectable hydrogel for the synchronous treatment of type 2 diabetes mellitus (T2DM) and associated complications.
In this study, Lixisenatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Lixisenatide.
Report a problemFND-3136111206
06AnimalNot a test of Lixisenatide aloneAnimal study (in vivo)Efficacy outcome
In diabetic mice, hydrogel lixisenatide metabolic results were superior or equivalent to twice-daily lixisenatide solution results.
In plain wordsIn mice, hydrogel lixisenatide metabolic results were better than or equivalent to twice-daily lixisenatide solution results.
Peptide
Lixisenatide
Outcome
MixedMetabolic outcomes versus solution
Study
mousen: not reported in source
Diabetic db/db mice
Comparator
Twice-daily lixisenatide solution for 30 days
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
These results were superior or equivalent to those of twice-daily injections of Lixi solution for 30 days, but the number of injections was markedly reduced from 60 to 3.
2 context sentences(design, population, supporting numbers)
Summary · context
Furthermore, three successive administrations of the abovementioned gel system within a month significantly increased the plasma insulin level, lowered glycosylated hemoglobin, and improved the pancreatic function of the animals.
Summary · context
Herein, we aimed to develop a long-acting delivery system of lixisenatide (Lixi), a glucose-dependent antidiabetic peptide, based on an injectable hydrogel for the synchronous treatment of type 2 diabetes mellitus (T2DM) and associated complications.
In this study, Lixisenatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Lixisenatide.
Report a problemFND-3136111207
07AnimalNot a test of Lixisenatide aloneAnimal study (in vivo)Efficacy outcome
In diabetic mice, hydrogel lixisenatide reduced injections from 60 to 3 compared with lixisenatide solution over 30 days.
In plain wordsIn mice, hydrogel lixisenatide required 3 injections versus 60 with lixisenatide solution.
Peptide
Lixisenatide
Outcome
DecreaseInjection count
Study
mousen: not reported in source
Diabetic db/db mice
Comparator
Twice-daily lixisenatide solution
Outcome group
Device usability · Metabolic and weight
Source sentences
Summary
These results were superior or equivalent to those of twice-daily injections of Lixi solution for 30 days, but the number of injections was markedly reduced from 60 to 3.
1 context sentence(design, population, supporting numbers)
Summary · context
Herein, we aimed to develop a long-acting delivery system of lixisenatide (Lixi), a glucose-dependent antidiabetic peptide, based on an injectable hydrogel for the synchronous treatment of type 2 diabetes mellitus (T2DM) and associated complications.
In this study, Lixisenatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Lixisenatide.
Report a problemFND-3136111208
08AnimalNot a test of Lixisenatide aloneAnimal study (in vivo)Efficacy outcome
In diabetic db/db mice, hydrogel lixisenatide improved hyperlipidemia.
In plain wordsIn mice, hydrogel lixisenatide improved high blood lipid levels.
Peptide
Lixisenatide
Outcome
Direction not reportedHyperlipidemia
Study
mousen: not reported in source
Diabetic db/db mice
Outcome group
Lipids · Metabolic and weight
Source sentences
Summary
Finally, an improvement in hyperlipidemia, augmentation of nerve fiber density, and enhancement of motor nerve conduction velocity in the gel formulation-treated db/db mice indicated that the sustained delivery of Lixi arrested and even ameliorated diabetic complications.
1 context sentence(design, population, supporting numbers)
Summary · context
Herein, we aimed to develop a long-acting delivery system of lixisenatide (Lixi), a glucose-dependent antidiabetic peptide, based on an injectable hydrogel for the synchronous treatment of type 2 diabetes mellitus (T2DM) and associated complications.
In this study, Lixisenatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Lixisenatide.
Report a problemFND-3136111209
09AnimalNot a test of Lixisenatide aloneAnimal study (in vivo)Efficacy outcome
In diabetic db/db mice, hydrogel lixisenatide increased nerve fiber density.
In plain wordsIn mice, hydrogel lixisenatide increased nerve fiber density.
Peptide
Lixisenatide
Outcome
IncreaseNerve fiber density
Study
mousen: not reported in source
Diabetic db/db mice
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
Finally, an improvement in hyperlipidemia, augmentation of nerve fiber density, and enhancement of motor nerve conduction velocity in the gel formulation-treated db/db mice indicated that the sustained delivery of Lixi arrested and even ameliorated diabetic complications.
1 context sentence(design, population, supporting numbers)
Summary · context
Herein, we aimed to develop a long-acting delivery system of lixisenatide (Lixi), a glucose-dependent antidiabetic peptide, based on an injectable hydrogel for the synchronous treatment of type 2 diabetes mellitus (T2DM) and associated complications.
In this study, Lixisenatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Lixisenatide.
Report a problemFND-3136111210
10AnimalNot a test of Lixisenatide aloneAnimal study (in vivo)Efficacy outcome
In diabetic db/db mice, hydrogel lixisenatide increased motor nerve conduction velocity.
In plain wordsIn mice, hydrogel lixisenatide increased motor nerve conduction speed.
Peptide
Lixisenatide
Outcome
IncreaseMotor nerve conduction velocity
Study
mousen: not reported in source
Diabetic db/db mice
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
Finally, an improvement in hyperlipidemia, augmentation of nerve fiber density, and enhancement of motor nerve conduction velocity in the gel formulation-treated db/db mice indicated that the sustained delivery of Lixi arrested and even ameliorated diabetic complications.
1 context sentence(design, population, supporting numbers)
Summary · context
Herein, we aimed to develop a long-acting delivery system of lixisenatide (Lixi), a glucose-dependent antidiabetic peptide, based on an injectable hydrogel for the synchronous treatment of type 2 diabetes mellitus (T2DM) and associated complications.
In this study, Lixisenatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Lixisenatide.
Report a problemFND-3136111211
11LabNot a test of Lixisenatide aloneIn vitro (cell-free)Pharmacokinetics
In laboratory release tests, the mixture hydrogel sustained lixisenatide release for up to 9 days.
In plain wordsIn lab tests, the mixture hydrogel sustained lixisenatide release for up to 9 days.
Peptide
Lixisenatide
Outcome
Not applicableSustained release in vitro
Study
n: not reported in source
Mixture hydrogel release system
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
Both in vitro and in vivo release studies demonstrated that the mixture hydrogel provided the sustained release of Lixi for up to 9 days, which was attributed to balanced electrostatic interactions between the positive charges in the peptide and the negative charges in the polymer carrier.
1 context sentence(design, population, supporting numbers)
Summary · context
Herein, we aimed to develop a long-acting delivery system of lixisenatide (Lixi), a glucose-dependent antidiabetic peptide, based on an injectable hydrogel for the synchronous treatment of type 2 diabetes mellitus (T2DM) and associated complications.
In this study, Lixisenatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Lixisenatide.
Report a problemFND-3136111201

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.